FENC Q3 2025 Earnings — Fennec Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

FENCFennec Pharmaceuticals Inc.

$220M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+78.7% YoY

Gross Profit

$12M94.7% margin

Operating Income

-$189,000-1.5% margin

Net Income

-$638,000-5.1% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+29.1%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

$1M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$49M

Total Liabilities

$54M

Stockholders' Equity

-$4M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$7M	+78.7%
Gross Profit	$12M	$6M	+110.1%
Operating Income	-$189,000	-$5M	+96.4%
Net Income	-$638,000	-$6M	+88.9%